万维提示：
1、投稿方式：在线投稿。
2、官网网址：https://www.thelancet.com/journals/laneur/home
3、投稿网址：http://www.editorialmanager.com/thelancetneurology
4、官网邮箱：editorial@lancet.com（编辑）
e.becker-barroso@lancet.com（编辑）
5、官网电话：+44 [0] 20 7424 4272（编辑）
6、期刊刊期：月刊，一个月出版一期。
2021年4月27日星期二
投稿须知
【官网信息】
Information for Authors
All Articles should, as relevant:
• Be up to 3500 words (4500 for randomised controlled trials) with 30 references (the word count is for the manuscript text only)
• Include an abstract (semistructured summary), with five paragraphs (Background, Methods, Findings, Interpretation, and Funding), not exceeding 300 words. Our electronic submission system will ask you to copy and paste this section at the “Submit Abstract” stage
• For randomised trials, the abstract should adhere to CONSORT extensions: abstracts (see Lancet 2008; 371: 281–83)
• When reporting Kaplan-Meier survival data, at each timepoint, authors must include numbers at risk, and are encouraged to include the number of censored patients.
• For intervention studies, the abstract should include the primary outcome expressed as the difference between groups with a confidence interval on that difference (absolute differences are more useful than relative ones). Secondary outcomes can be included as long as they are clearly marked as secondary and all such outcomes are reported
• Use the recommended international non-proprietary name (rINN) for drug names. Ensure that the dose, route, and frequency of administration of any drug you mention are correct
• Use gene names approved by the Human Gene Organisation.
Novel gene sequences should be deposited in a public database (GenBank, EMBL, or DDBJ), and the accession number provided.
Authors of microarray papers should include in their submission the information recommended by the MIAME guidelines. Authors should also submit their experimental details to one of the publicly available databases:
ArrayExpress or GEO
• Include any necessary additional data as part of your EM submission
• All accepted Articles should include a link to the full study
protocol published on the authors’ institutional website (see Lancet 2009; 373: 992 and Lancet 2010; 375: 348)
• We encourage researchers to enrol women and ethnic groups
into clinical trials of all phases, and to plan to analyse data by sex and by race
• For all study types, we encourage correct use of the terms sex (when reporting biological factors) and gender (when reporting identity, psychosocial, or cultural factors). Where possible, report the sex and/or gender of study participants, and describe the methods used to determine sex and gender.
Separate reporting of data by demographic variables, such as age and sex, facilitates pooling of data for subgroups across studies and should be routine, unless inappropriate. Discuss the influence or association of variables, such as sex and/or gender, on your findings, where appropriate, and the limitations of the data.
……
